✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Lapachone is an investigational drug.
There have been 6 clinical trials for Lapachone. The most recent clinical trial was a Phase 1 trial, which was initiated on December 29th 2011.
The most common disease conditions in clinical trials are Neoplasms, Metabolic Syndrome X, and Metabolic Syndrome. The leading clinical trial sponsors are University of Texas Southwestern Medical Center, ArQule, and ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.).
Recent Clinical Trials for Lapachone
|ARQ761 + PARP Inhibitor in Refractory Solid Tumors||University of Texas Southwestern Medical Center||Phase 1|
|ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer||University of Texas Southwestern Medical Center||Phase 1|
|Clinical Trial of ARQ 761 in Advanced Solid Tumors||ArQule||Phase 1|